US98422E1038
US98422E1038
Xeris Biopharma Holdings, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 60/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±67.0% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.8x).
Beta (Market Relation)
0.84x
DefensiveVolatility (5Y p.a.)
67.0% p.a.
5-Year HorizonMax Drawdown (5Y)
-64.8%
5-Year HorizonSharpe Ratio
0.52
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +24.3% |
| 3 Years | 60.6% | -47.2% | 1.31 | +82% |
| 5 Years | 67.0% | -64.8% | 0.52 | +37.3% |
| 10 Years | 78.2% | -96.2% | -0.13 | — |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Unprofitable business model: The company is currently generating net losses.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (67.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -96.2% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
8 ISS Score: 8 / 10
Audit Risk
5 ISS Score: 5 / 10
Board Risk
8 ISS Score: 8 / 10
Short Ratio
5.10